Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.

Leukemia · 2022 · PMC9061287 · PMID 35091659

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significancep = 0.06so close (0.05 < p ≤ 0.1)

Obesity (BMI ≥ 30) was associated with longer time to disappearance (OR: 0.60, 95% CI: 0.35–1.03), with median time of 7.1 (95% CI: 4.4–10.4) and 5.8 (95% CI: 4.3–6.3) months in patients with BMI ≥ 30 and <30, respectively, but this did not reach statistical significance ( p = 0.06).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.